Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

Trial Details

NCT ID

NCT06491472

Phase

PHASE2

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• Ivonescimab
• Gemcitabine
• Nab paclitaxel
• SBRT

Locations (sample)

• Wuhan, China|30.58333,114.26667

Key Eligibility Criteria

• Be able and willing to provide written informed consent and comply with all requirements of study participation (including all study procedures).
• Histologically- or cytologically-confirmed diagnosis of pancreatic ductal adenocarcinoma (including adenosquamous carcinoma)
• Have a life expectancy of at least 3 months.
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.